Clinical Trial Update: A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing TAS-102 with topotecan or amrubicin for small cell lung cancer after platinum therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)
• TAS-102 (trifluridine/tipiracil)
• Topotecan (topotecan)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Small Cell Lung Cancer (SCLC) | Phase 2 | Status: TERMINATED